US OptionsDetailed Quotes
SCLX250516C1000
- 0.00
- 0.000.00%
15min DelayTrading May 2 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-81.68%PremiumMay 16, 2025Expiry Date4.46Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Scilex Holding Stock Discussion
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
Wednesday, 30th April at 1:46 pm
PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ: SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced th...
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
Tuesday, 22nd April at 9:00 am
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ: SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acqu...
FDA Approval: Scilex's Revolutionary Liquid Heart Drug Secures Rare Disease Status
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
Wednesday, 16th April at 2:12 pm
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Pericarditis is an inflammation of the pericardium, the sac-like membrane that surrounds and protects the heart. It occurs when the pericard...
Revolutionary 15-Minute Migraine Relief: Scilex's ELYXYB Wins Canadian Approval
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada
Tuesday, 15th April at 9:00 am
ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1
According to marke...
Scilex Holding Co - Receives Health Canada Approval for Elyxyb for Migraine Treatment
whys there two super high price order ?
8 MINUTES AGO, 4:35 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to...
No comment yet